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Abstract 
Hypertensive heart disease is often associated with a preserved left ventricular 
ejection fraction despite impaired myocardial shortening. We investigated this 
paradox in 55 hypertensive patients (52±13 years, 58% male) and 32 age- and sex-
matched normotensive control subjects (49±11 years, 56% male) who underwent 
cardiac magnetic resonance at 1.5T. Long-axis shortening (R=0.62), midwall 
fractional shortening (R=0.68) and radial strain (R=0.48) all reduced (p<0.001) as 
end-diastolic wall thickness increased. However, absolute wall thickening (defined as 
end-systolic minus end-diastolic wall thickness) was maintained, despite the reduced 
myocardial shortening. Absolute wall thickening correlated with ejection fraction 
(R=0.70, p<0.0001). In multiple linear regression analysis, increasing wall thickness 
by 1mm independently increased ejection fraction by 3.43 percentage points 
(adjusted β-coefficient: 3.43 [2.60–4.26], p<0.0001). Increasing end-diastolic wall 
thickness augments ejection fraction through preservation of absolute wall 
thickening. Left ventricular ejection fraction should not be used in hypertensive 
heart disease without correction for degree of hypertrophy. 
 
 
 
Text 
Introduction 
In systemic hypertension, left ventricular hypertrophy (LVH) may occur in the face of 
increased afterload (1). The development of hypertensive LVH is pathological and is 
an independent predictor for sudden cardiac death(2), ventricular arrhythmias(3), 
coronary artery disease(4) and heart failure(5), which is often in the context of a 
normal left ventricular ejection fraction (LVEF). The hypertrophied hypertensive 
myocardium is associated with reduced long-axis shortening (LS), yet the left 
ventricular ejection fraction (LVEF), which is a traditional marker of LV systolic 
function, remains in the normal range(6), leading some to believe that hypertensive 
heart disease is a diastolic disorder. The apparent paradox of global myocardial 
systolic long-axis dysfunction but normal LVEF has previously been explained by a 
“compensatory increase in short-axis shortening”(7). However, observational data 
does not support this hypothesis; for example, there are abnormalities of both 
midwall and longitudinal fractional shortening in hypertensive hypertrophic left 
ventricular disease(8)(9)(10). 
 
An alternative theoretical explanation argues that an increase in end-diastolic left 
ventricular wall thickness (EDWT) leads to increased end-systolic left ventricular wall 
thickness (ESWT) and a correspondingly augmented absolute wall thickening (AWT), 
where AWT is the difference between ESWT and EDWT. Assuming no significant 
change in the external diameter of the left ventricle during systole(11), the resultant 
absolute displacement of the endocardial border could be normal and therefore 
LVEF maintained. This concept has been demonstrated by mathematical modeling of 
 
 
 
concentric LVH (12)(13). Such mathematical modeling controls for, and therefore 
removes, the potential impact of other variables such as body surface area, heart 
rate, blood pressure, ventricular-arterial coupling, peripheral vascular resistance and 
abnormalities in left ventricular relaxation.  
 
We sought to accurately determine the biophysical relationship between EDWT, 
longitudinal and midwall myocardial shortening, AWT and LVEF in a human 
hypertensive cohort using cardiac magnetic resonance (CMR) since it is the gold-
standard for non-invasively assessing left ventricular (LV) mass and volume(14). A 
detailed assessment of the relationship between these variables will aid better 
understanding of the pathophysiology of hypertensive heart disease and may have 
important implications for refining our understanding of the mechanisms of heart 
failure with normal ejection fraction (HFNEF), with implications for its treatment. 
 
Materials and Methods  
Study subjects 
Fifty-five hypertensive subjects (age: 52 ± 13 years, gender: 58% male, office SBP: 
174 ± 29mmHg, office DBP: 98 ± 16mmHg) were recruited from the Bristol Heart 
Institute tertiary hypertension clinic between 2011 and 2013. Baseline demographic 
and clinical characteristics were recorded. In order to investigate hypertensive LVH, 
exclusion criteria consisted of clinical or CMR evidence of any concomitant 
myocardial pathology that may confound the hypertrophic response (e.g. previous 
 
 
 
myocardial infarction, moderate-severe valvular heart disease, dilated 
cardiomyopathy, suspected athlete’s heart, hypertrophic or infiltrative 
cardiomyopathy).  
 
Average office systolic (SBP) and diastolic blood pressures (DBP) were acquired in all 
subjects after seated rest from both arms, assessed using standard automated 
sphygmomanometry with an appropriately-sized cuff(15). Standard 24-hour 
ambulatory blood pressure monitoring (ABPM) was also performed(16).  
 
A cohort of 32 age- and sex-matched normotensive control subjects (age: 49 ± 11 
years, gender 56% male, office SBP: 126 ± 12mmHg, office DBP: 77 ± 10mmHg) 
healthy volunteers free from cardiovascular disease, with normal blood pressure and 
ECG, and on no regular medication, were used as an age- and sex-matched control 
group. 
 
The study complied with the Declaration of Helsinki. The local research ethics 
committee confirmed that this study conformed to the governance arrangements 
for research ethics committees. Subjects provided written consent for their CMR 
images to be used for research.  
 
CMR protocol 
All CMR studies were performed at 1.5T (Avanto, Siemens, Erlangen, Germany) using 
a spine coil, a body array coil and retrospective electrograph (ECG) triggering by 
 
 
 
specialist CMR technicians. Steady-state free precession (SSFP) end-expiratory 
breath-hold cines were acquired in the standard 4-chamber, 2-chamber and 3-
chamber cardiac long-axis planes and in the LV short-axis from the atrioventricular 
ring to the apex. Representative CMR parameters were as follows: repetition time 
(TR) 40.05ms, echo time (TE) 1.13ms, slice thickness 8mm, no interslice gap, field of 
view 260 x 320mm, flip angle 75o, in-plane voxel size 2 x 2mm.  
 
CMR analysis 
All CMR analysis was performed by a single CMR reader, with > 4 years of CMR 
experience, using cvi42 software (Circle Cardiovascular Imaging Solutions 
Incorporated, Calgary, Canada). LV volumes, LVEF and LV mass were estimated using 
established clinical methods as described previously(17). Mass to volume ratio (M/V) 
was calculated as previously described(18). This data was acquired blinded to the 
myocardial fractional shortening measurements, and vice versa. Changes in lengths 
in the longitudinal and radial directions of the myocardium between end-diastole 
and end-systole have recently been demonstrated to represent a simple technique 
to quantify myocardial strain relative to both in vivo myocardial tagging and 
validated finite element computation modeling techniques(19). Consequently, we 
used a 6-point mitral annular plane systolic excursion indexed to the LV end-diastolic 
length as a measure of global long-axis shortening as described previously(17). 
EDWT and ESWT were measured in the middle of each of the basal and mid LV 
myocardial segments on the long-axis cines with measurements performed 
perpendicular to the LV wall. Measurements of the thickness of the apical segments 
 
 
 
were prone to partial volume averaging, particularly at end-systole, due to the 
conical configuration of the LV and therefore were not included in the analysis. 
EDWT has previously been demonstrated to have better levels of inter and intra-
observer agreement when measured from long-axis compared to short axis 
cines(20). Furthermore, it was easier to take into account the effect of through-plane 
motion of the mitral valve during systole using long-axis cines compared to the 
short-axis cines using mitral valve plane tracking software (cvi42, Circle 
Cardiovascular Imaging Solutions Incorporated, Calgary, Canada). Papillary muscles 
and trabeculae were excluded from wall thickness measurements. Relative wall 
thickness was defined as EDWT indexed to left end-diastolic diameter. AWT was 
defined as the absolute difference between ESWT and EDWT. Radial strain was 
defined as the percentage increase in wall thickness (i.e. engineering strain or 
relative wall thickening). LV internal diameters at end-diastole (LVIDd) and at end-
systole (LVIDs) were measured at the LV basal and mid levels from the long-axis 
cines. All measurements were repeated twice and the mean value used for 
subsequent analysis. Midwall circumferential fractional shortening (mFS) was 
estimated using the following established equation, which has been described 
previously(10): 
 
mFS (%) = ((LVIDd + EDWT) – (LVIDs + H)) / (LVIDd + EDWT) x 100 
 
Where:  
 
H = ((LVIDd + EDWT)3 – (LVIDd)3 + (LVIDs)3)1/3 - LVIDs  
 
 
 
 
Statistical analysis 
Statistical analysis was generated using the Real Statistics Resource Pack software 
(Release 3.2.1) and using SPSS v.21 (Armonk, NY, USA: IBM Corp). Categorical 
variables were analyzed using Fisher’s exact tests. Normally distributed continuous 
variables were expressed as mean ± standard deviation and compared using 
unpaired Student’s T tests or one-way analysis of variance with Bonferroni post-hoc 
correction for between groups comparisons, as appropriate. Multiple linear 
regression analysis was performed to investigate independent determinates of 
EDWT, LAS and mFS on LVEF. The impact of multi-collinearity was excluded by 
acceptable values in variance inflation factor tests. Reproducibility was assessed by 
intra-class correlation coefficient (ICC) (two-way mixed, absolute agreement, 
average measures). The intra-observer intra-class correlation coefficient for EDWT 
was 0.962 (95% confidence interval: 0.956–0.968), for ESWT was 0.966 (0.959–
0.971), LV end diastolic length was 0.987 (0.984–0.989) and for LV end systolic 
length was 0.990 (0.987–0.992). Statistical significant was set at two-tailed p<0.05. 
Results 
Demographics 
The demographic and baseline clinical data for hypertensive subjects and 
normotensive controls are documented in Table 1. The study sample was stratified 
into tertiles by EDWT. There were significantly more female subjects with EDWT < 
9mm compared to both EDWT 9 -11m and EDWT > 11mm respectively, P < 0.05. No 
other demographics differences were demonstrated across the study population. 
 
 
 
There were no statistically significant differences in the anti-hypertensive medication 
regimens between the hypertensive cohorts. There were step-wise increases in both 
M/V and RWT with increasing EDWT, consistent with increasing concentric LVH with 
increasing EDWT in our sample of patients. EDWT correlated with office SBP (R = 
0.43, P < 0.001) and office DBP (R = 0.32, P < 0.005) but did not correlated with 
ABPM SBP (R = 0.24, P = 0.12), ABPM SBP (R = 0.18, P = 0.27) or ABPM MAP (R = 
0.18, P = 0.27). 
 
Impact of increasing EDWT on mFS, LS and RS 
There was a strong positive significant correlation between mFS and LAS (R=0.73, 
p<0.001) (Figure 1A). Both mFS (R=0.84, p<0.001) and LAS (R=0.64, p<0.001) 
correlated significantly with RS (Figure 1B and 1C). EDWT correlated with mFS 
(R=0.68, p<0.001) (Figure 2A), LAS (R=0.62, p<0.001) (Figure 2B) and RS (R=-0.48, 
p<0.001)(Figure 2C). The hypertensive cohort with EDWT >11mm had significantly 
lower LAS and mFS compared to hypertensives with EDWT 9 – 11mm, hypertensives 
with EDWT <9mm and normotensive controls, on pairwise comparisons with 
Bonferroni adjustment (Table 2). 
 
Impact of increasing EDWT on ESWT and AWT 
As EDWT increased, there was an increase in end-systolic wall thickness (R=0.92, 
p<0.001) (Figure 3A) but and an increase AWT (R= 0.43, p<0.005) (Figure 3B). There 
 
 
 
were significant increases in AWT from all hypertensive subgroups compared to 
normotensive controls (Table 2) and there was significant increases in AWT from 
hypertensive subjects with EDWT 9 – 11m and EDWT > 11m compared to EDWT < 
9mm respectively (Table 2). 
 
Impact of increasing EDWT and AWT on LVEF 
Despite reduction in mFS, LAS and RS with increasing EDWT, there was a borderline 
significant weak correlation between EDWT and LVEF (R=0.26, p=0.05) (Figure 3C). 
Absolute wall thickening correlated significantly with LVEF (R=0.70, p<0.0001) 
(Figure 3D). 
 
Impact of increasing EDWT on indexed EDV, indexed ESV and indexed SV 
Increasing EDWT negatively correlated with both indexed EDV (R=-0.37, p<0.05) and 
indexed ESV (R=-0.30, p<0.05). However, the reduction in both indexed EDV and 
indexed ESV with increasing EDWT resulted in no significant difference in the 
indexed stroke volume (R=-0.081, p=0.55). 
 
 
Multiple linear regression analysis 
Regression analysis was performed using variables that have a biophysically plausible 
and direct influence on LVEF. LVEF was set as the dependent variable and EDWT, LAS 
and mFS as independent variables. All variables were continuous. EDWT, LAS and 
 
 
 
mFS were all independently and positively correlated with LVEF (Table 3). Essentially, 
a 1 mm increase in EDWT would independently account for an increase in the LVEF 
by an absolute value of 3.43%. The increase in EDWT compensates for the 
independent reduction in LVEF by an absolute value of 2.01% and 1.05% for a 1.00% 
absolute reduction in LAS and mFS by respectively. 
 
Discussion 
Our study investigated the impact of EDWT on LVEF in hypertensive heart disease 
using segmental engineering strain measurements derived from CMR, the gold-
standard non-invasive cardiac imaging modality for LV wall thickness and function, in 
a sample of 55 hypertensive and 32 normotensive subjects.  
 
The pathophysiology of LVH and its functional consequences are incompletely 
understood.  However, the concept that left ventricular (LV) wall geometry affects 
the LVEF is longstanding(21). De Dumesnil et al. proposed that wall thickening is the 
direct reflection of shortening that occurs in the circumferential and longitudinal 
directions(22). Subsequent work by Rademakers et al. demonstrated the importance 
of cross-fibre shortening in determining wall thickening in a canine model using 
tagged cardiovascular magnetic resonance (CMR)(23). More recently, the notion that 
LV geometry impacts on its ejection fraction has been reaffirmed by an 
echocardiographic study by Aurigemma et al.(24), which showed that elderly 
subjects with high relative wall thickness maintained their LVEF despite depressed 
 
 
 
midwall fractional shortening. Palmon et al. demonstrated that both longitudinal and 
circumferential shortening were reduced in hypertensive subjects with LVH and a 
normal ejection fraction, using tagging CMR(25). Furthermore, Vinch et al. 
demonstrated significantly lower midwall fractional shortening (mFS) in patients 
with hypertensive heart disease compared to normal controls, despite unchanged 
mean endocardial shortening and ejection fraction(26). Similar findings were 
demonstrated by Koh and colleagues(27). More recently, Mizuguchi and colleagues 
showed reduced longitudinal, circumferential and radial strain in hypertensive 
patients with concentric hypertrophy in an echocardiographic study(6).  
 
It is therefore clear that LVH is associated with abnormalities of both midwall and 
longitudinal fractional shortening. However, the reason why LVEF, a traditional 
marker of LV systolic function, usually remains in the normal range despite these 
abnormalities is unclear. A theoretical explanation argues that an increase in end-
diastolic left ventricular wall thickness (EDWT) leads to increased end-systolic left 
ventricular wall thickness (ESWT) and a correspondingly augmented absolute wall 
thickening (AWT), where AWT is the difference between ESWT and EDWT. Assuming 
no significant change in the external diameter of the left ventricle during systole(11), 
the resultant absolute displacement of the endocardial border could be normal and 
therefore maintain LVEF. This concept has been demonstrated by mathematical 
modeling of concentric LVH (12). Furthermore, in an trans-esophageal 
echocardiographic study of 15 patients with hypertension, Frielingsdorf et al. 
demonstrated that absolute and fractional wall thickening was inversely related to 
 
 
 
EDWT, but did not investigate the relationship between these variables and 
LVEF(28). 
 
Our findings that increasing EDWT was accompanied by reduced myocardial 
longitudinal and circumferential shortening are consistent with the existing 
literature. However, we additionally demonstrate, for the first time, the independent 
and significant relationships between both longitudinal and circumferential 
shortening and EDWT on LVEF using multiple linear regression analysis. Whilst an 
increase in EDWT independently results in a significant increase in LVEF, it is 
associated with a reduction in LAS, mFS and RS, which in turn, significantly and 
independently lowers LVEF.  
 
The importance of AWT 
In spite of the worsening strain abnormalities with increasing EDWT in our cohort, 
both LVEF and indexed SV remained in the normal range for all EDWT values. Our 
results offer further insights to help explain this apparent paradox. As EDWT 
increased, we also demonstrated a corresponding increase in wall thickness at end-
systole. As a result, there was a maintained absolute wall thickening over the range 
of end diastolic wall thicknesses investigated. Consequently, the absolute 
endocardial displacement remained normal with increased EDWT, despite reduced 
myocardial shortening. The maintenance of AWT with increasing EDWT is not due to 
compensatory radial thickening because there is a concomitant reduction in radial 
strain. We provide evidence that the preservation of AWT, and therefore LVEF, is 
secondary to the degree of LVH defined by EDWT. Of note, the influence of a given 
 
 
 
amount of AWT in smaller left ventricles will have a greater impact on LVEF. Our 
study provides in vivo validation of this mechanism described in mathematical 
modeling experiments of concentric LVH(12). In summary, a ventricle with normal 
EDWT, normal LAS and normal mFS will result in similar AWT as a ventricle with 
concentric LVH, reduced LAS, mFS and RS. The AWT is an important determinant of 
the LVEF and indexed SV in both these hypothetical scenarios. Our results show how 
there can be important abnormalities of systolic function, defined by reduced 
myocardial shortening, and yet a normal LVEF and hence explain why LVEF is a poor 
marker of systolic dysfunction in the context of LVH. 
 
Hypertensive remodelling 
Left ventricular remodeling is postulated to be a constructive adaptive physiological 
response to result in a normalization of stroke volume(29). We have demonstrated 
that the indexed EDV and indexed ESV reduce with increasing EDWT but indexed SV 
remains within the normal range as EDWT increases, consistent with previous 
mathematical modeling(30). This lends weight to the hypothesis that hypertensive 
LVH occurs concurrently or before the abnormality causing contractile 
dysfunction(30). In the context of hypertension, reduced contractility of the 
hypertrophied myocardium is postulated to occur, at least in animal models, as a 
consequence of production of different myosin heavy chain isoforms mediated by 
changes in expression of myocardial contractile and metabolic proteins through 
secondary messenger cell signaling pathways such as phosphoinositides and proto-
oncogenes(31). 
 
 
 
 
Implications for heart failure with preserved ejection fraction (HFpEF) 
Our findings may have important implications for understanding the 
pathophysiology of HFpEF. The term HFpEF describes patients with a left ventricular 
ejection fraction (LVEF) >45-50% but clinical features of heart failure(7). HFpEF is a 
common disease, affecting approximately 50% of patients with heart failure(32). 
Myocardial shortening abnormalities are common in HFpEF(33) and patients often 
have hypertension and concentric LVH(34). As AWT compensates for myocardial 
shortening impairment in hypertensive heart disease with normal LVEF and normal 
indexed SV, it is perplexing why some patients develop clinical symptoms of heart 
failure in the context of hypertensive heart disease. This is best explained by the 
blunted cardiovascular response to exercise with failure to augment SV and cardiac 
index on exertion(35) and reduced contractile reserve(36). 
 
Left ventricular mass is an important determinant of risk in hypertensive heart 
disease with differing risk dependent on the remodeling pattern(37). We have 
shown the detailed biophysical relationships between EDWT and myocardial 
shortening, LVEF and ventricular volumes. We suggest that geometric patterns seen 
in hypertension may be explained by the combination of wall thickness and 
myocardial shortening. A combination of both EDWT and myocardial shortening may 
give incremental prognostic information over the traditional marker of LVEF alone. 
 
Limitations 
The study population size was modest. However, our correlations with AWT and our 
multiple linear regression results were highly significant suggestive sample size was 
 
 
 
adequate. The latter is likely related to the improved accuracy and reproducibility of 
CMR compared to echocardiography, which affords a marked reduction in sample 
size for the same statistical power(38). Our study was limited to hypertensive 
subjects attending a tertiary hypertension clinic. Most subjects are likely to have 
moderate to severe hypertension, which may preclude extrapolation beyond this 
particular cohort. However, the study was primarily designed to assess the 
interaction of EDWT on LVEF and not the impact of severity of hypertension. 
Nonetheless, there were no significant differences in office systolic or diastolic blood 
pressure across the subgroups with EDWT <9mm, 9 – 11mm and >11mm 
respectively (Table 1). Furthermore, modeling data would suggest that only a mild 
increase in EDWT (e.g. > 12mm) is necessary to significantly increase LVEF(12)(39). 
Obesity can affect LV remodeling and hypertrophy(40) and whilst obesity was 
common in our sample, there were not significant differences in mean BMI across 
the subjects (Table 1). 
 
Engineer’s strain was calculated directly by measuring LAS and RS manually. Similar 
techniques quantifying changes in myocardial length and thickness at end-diastole 
and end-systole have been validated against myocardial tagging and finite element 
models(19). However, we elected to calculate mFS using a widely used and 
previously validated equation(10) because there is a large circumferential strain 
gradient (approximately 3-36%) across the wall of the myocardium, with the 
subendocardial myocardium being displaced more than the epicardial 
myocardium(41), consequently the midwall myocytes cannot be easily tracked 
through the cardiac cycle as their position relative to the endocardial and epicardial 
 
 
 
borders changes continually during LV contraction. As a result, tracking-derived 
values for circumferential strain may not be representative of mFS. Nevertheless, it 
should be noted that the equation used to estimate mFS makes assumptions about 
left ventricular geometry, as it presumes the external and internal contours are 
ellipsoidal in systole and diastole. However, there are currently no alternative 
validated methods. In addition, assumptions are made in the calculations that there 
is no loss in myocardial muscle volume during contraction even though there is likely 
to be a small reduction in volume as a result of vascular compression. Finally, 
through-plane motion was visually taken into account using our method but this 
phenomenon may degrade the accuracy of strain values generated from strain 
software in the short axis. Our relatively simple wall thickness measuring method, 
but using a gold-standard imaging technique, was reproducible. Further work is 
required to confirm whether similar techniques can be applied to other settings, 
potentially opening the possibility to explore pre-existing large cardiac imaging 
databases. 
 
In light of the limitations, our calculations should only be considered as improved 
approximations and, in our view, the trends observed and concepts described are 
likely to be valid and are concordant with recent modeling studies(42). 
 
Clinical implications 
Hypertensive heart disease is often associated with a normal ejection fraction with 
the supposition that ventricular systolic function is also normal. We, however, have 
 
 
 
shown that myocardial shortening and strain gradually decrease as wall thickness 
increases despite a maintained ejection fraction. We have shown that the absolute 
wall thickening is a major determinant of ejection fraction and that, in turn, absolute 
wall thickening is determined by both myocardial shortening and wall thickness. 
Myocardial shortening (and therefore function) and radial strain are reduced in the 
presence of left ventricular hypertrophy and normal ejection fraction. There is no 
compensatory increase in radial function that normalizes the ejection fraction when 
long-axis shortening is abnormal as previously thought. The ejection fraction is a 
poor measure of systolic function particularly in the setting of hypertrophic 
ventricles. Our findings have important clinical, physiological and prognostic 
implications. 
 
Conclusion 
Our study quantified, for the first time, the relationships between left ventricular 
myocardial shortening (longitudinal shortening, midwall fractional shortening and 
radial strain), end-diastolic wall thickness, absolute wall thickening, and ejection 
fraction. Our analyses provide additional novel insights into the mechanism by which 
hypertensive patients can have significant contractile dysfunction and a normal 
ejection fraction. We confirm previous work showing reduced long-axis shortening 
and midwall fractional shortening in the setting of a normal LVEF and indexed stroke 
volume. We demonstrate for the first time, using multiple linear regression analysis, 
that LAS, mFS and EDWT are each significantly and independently correlated with 
 
 
 
LVEF. As EDWT increases, AWT is maintained which preserves LVEF and indexed SV 
despite falls in both long-axis and midwall fractional shortening. The maintenance of 
AWT is simply a result of increased EDWT and decreased myocardial fractional 
shortening.  
 
Importantly, LVEF and the term systolic function are not synonymous and LVEF 
should not be used as an accurate index of LV function in the presence of LVH, 
without correction for the degree of LV end-diastolic wall thickness. 
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Figure legends  
Figure 1: Scatter graphs for hypertensive subjects and normotensive controls: A) 
showing the relationship of midwall fractional shortening to long-axis shortening, B) 
showing the relationship of radial strain to midwall fractional shortening and C) 
showing the relationship of radial strain to long-axis shortening. 
Figure 2: Scatter graphs for hypertensive subjects and normotensive controls: A) 
showing the relationship of midwall fractional shortening to mean end-diastolic wall 
thickness, B) showing the relationship of long-axis shortening to mean end-diastolic 
wall thickness and C) showing the relationship of radial strain to mean end-diastolic 
wall thickness. 
 
 
 
Figure 3: Scatter graphs for hypertensive and normotensive controls: A) showing the 
relationship of EDWT to ESWT, B) showing the relationship of EDWT to AWT, C) 
showing the relationship of EDWT to LVEF and D) showing the relationship of AWT to 
LVEF. 
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Table 1: Demographics and baseline clinical characteristics of hypertensive subjects and normotensive controls. 
 
 
   Controls   EDWT < 9 mm  EDWT 9 – 11 mm  EDWT >11 mm P-value 
    (n = 32)  (n = 16)  (n = 21)   (n = 18) 
Demographics 
Age (years)   49 ± 11  47 ± 15  55 ± 10   52 ± 11  = 0.112 
Gender (% male)  56   13   76    78   < 0.001*  
BMI (kg/m2)   26 ± 5   29 ± 4   30 ± 4    32 ± 5   < 0.001† 
 
Blood pressure 
Office SBP (mmHg)  126 ± 12  174 ± 27  172 ± 30   176 ± 32  < 0.001‡ 
Office DBP (mmHg)  77 ± 10  97 ± 16  100 ± 17   98 ± 17  < 0.001‡ 
ABPM SBP (mmHg)  …   154 ± 28  150 ± 12   168 ± 23  = 0.087 
ABPM DBP (mmHg)  …   89 ± 18  90 ± 9    97 ± 13  = 0.309 
ABPM MAP (mmHg)  …   108 ± 21  105 ± 10   115 ± 13  = 0.192 
 
Anti-HTN medication 
No. anti-HTN medications …   3 ± 2   4 ± 2    4 ± 2   = 0.266 
ACEi (%)   …   38   71    39   = 0.057 
ARB (%)   …   25   33    61    = 0.074 
Calcium channel blocker (%) …   44   62    61   = 0.496 
Thiazide diuretic (%)  …   44   43    28   = 0.555 
Loop diuretic (%)  …   13   5    17   = 0.494 
K+ sparing diuretic (%) …   75   86    72   = 0.856 
Beta-blocker (%)  …   44   38    44   = 0.923 
 
 
 
 
* EDWT < 9mm vs all other subgroups 
† Controls vs EDWT 9 – 11mm and EDWT > 11mm, respectively 
‡ Control vs all other subgroups 
 
EDWT = end-diastolic wall thickness, BMI = body mass index, SBP = systolic blood pressure, DBP = diastolic blood pressure, ABPM = 24-hour 
ambulatory blood pressure monitor, MAP = mean arterial pressure, anti-HTN = anti-hypertensive, ACEi = Angiotensin converting enzyme 
inhibitor, ARB = angiotensin II receptor blocker 
 
 
 
 
 
Table 2: Left ventricular volumetric, myocardial thickness and myocardial shortening data for hypertensive subjects and normotensive 
controls. 
 
 
   Controls   EDWT < 9 mm  EDWT 9 – 11 mm  EDWT >11 mm P-value 
    (n = 32)  (n = 16)  (n = 21)   (n = 18) 
LV volumetrics 
LV-EF (%)   64 ± 7   64 ± 6   67 ± 8    67 ± 11  = 0.422 
Indexed EDV (ml/m2)  77 ± 18  90 ± 11  83 ± 17   81 ± 17  = 0.109 
Indexed ESV (ml/m2)  29 ± 11  32 ± 8   28 ± 12   27 ± 11  = 0.586 
Indexed SV (ml/m2)  48 ± 12  56 ± 5   55 ± 10   55 ± 13  = 0.146 
 
Myocardial mass & thickness 
Indexed LV mass (g/m2) 58 ± 11  81 ± 20  88 ± 11   118 ± 16  < 0.001* † 
RWT (mm/ml)   0.09 ± 0.02  0.11 ± 0.02  0.13 ± 0.03   0.14 ± 0.03  < 0.01‡ § 
M/V (g/ml)   0.76 ± 0.13  0.91 ± 0.14  1.08 ± 0.20   1.45 ± 0.27  < 0.05¶ ∆ 
AWT (mm)   4.4 ± 0.9  5.4 ± 1.4  6.5 ± 1.2   6.8 ± 1.3  < 0.05* ** 
 
Myocardial shortening 
Long-axis shortening (-%)  16 ± 2   13 ± 3   11 ± 2    8 ± 2   < 0.005‡ † 
Radial strain (%)  62 ± 15  68 ± 15  65 ± 12   52 ± 12  < 0.05†† 
mFS (-%)   18 ± 2   20 ± 2   18 ± 3    15 ± 3   < 0.001† 
 
 
 
 
 
 
 
* Control vs all other subgroups 
† EDWT > 11mm vs all other subgroups 
‡ Controls vs EDWT 9 – 11mm and EDWT > 11mm, respectively 
§ EDWT > 11mm vs EDWT < 9mm 
¶ EDWT > 11mm vs all other subgroups 
∆ EDWT 9 – 11mm vs all other subgroups 
** EDWT < 9mm vs all other subgroups 
†† EDWT > 11mm vs EDWT 9 – 11mm and EDWT < 9mm, respectively 
 
EDWT = end-diastolic wall thickness, LV-EF = left ventricular ejection fraction, EDV = end-diastolic volume, ESV = end-systolic volume, SV = 
stroke volume, LV = left ventricular, RWT = relative wall thickness, M/V = mass to volume ratio, AWT = absolute wall thickening, mFS = midwall 
fractional shortening 
 
 
Table 3. Multiple linear regression analysis 
 
Variable Univariate coefficient of regression (95% CI) p-value  Multivariate coefficient of regression (95% CI) p-value 
EDWT  0.91 (-0.01 – 1.82)     0.051   3.43 (2.60 – 4.26)     < 0.0001 
LAS  0.86 (0.06 – 1.66)     0.035   2.01 (1.29 – 2.74)     < 0.0001 
mFS  0.906 (0.23 – 1.59)     < 0.01   1.05 (0.26 – 1.84)     < 0.01 
 
CI = confidence interval, EDWT = end-diastolic wall thickness, LAS = long-axis fractional shortening mFS = mid-wall fractional shortneing 
